# OEM/ODM Custom Assay Development Workflow for POCT
## Abstract
Custom assay development requires structured collaboration between POCT manufacturers and reagent suppliers. This application note outlines the OEM/ODM development workflow for lateral flow immunoassays, molecular diagnostics, and TRF platforms, from biomarker selection to regulatory submission.
## Introduction
IVD companies increasingly outsource assay development to specialized partners to reduce time-to-market and leverage existing expertise. A clear development workflow ensures efficient communication, milestone tracking, and successful technology transfer.
Due Bio, established in 1987, provides end-to-end IVD Reagents OEM/ODM services including biomarker validation, prototype development, scale-up manufacturing, and regulatory documentation support for lateral flow strips and POCT platforms.
## Materials Required
– Target biomarker specifications (clinical sensitivity/specificity requirements)
– Sample matrix information (serum, plasma, whole blood, urine, saliva)
– Intended use statement (screening, diagnosis, monitoring)
– Target market regulatory pathway (FDA 510k, CE-IVD, NMPA)
– Project timeline and budget constraints
## Step-by-Step Protocol
1. **Feasibility Assessment (Weeks 1-4)**: Review biomarker literature, assess antibody availability, evaluate sample matrix compatibility. Deliverable: Feasibility report with go/no-go recommendation.
2. **Prototype Development (Weeks 5-16)**: Develop capture/detection reagents, optimize buffer formulations, build alpha prototypes (lateral flow strips or cartridge). Deliverable: 3 prototype lots with preliminary performance data.
3. **Analytical Validation (Weeks 17-28)**: Determine LOD, linearity, precision, interference, hook effect. Test 100+ clinical samples. Deliverable: Analytical validation report per CLSI guidelines.
4. **Scale-Up & Technology Transfer (Weeks 29-40)**: Optimize manufacturing process, establish QC protocols, train client team. Deliverable: Pilot production (1000 units) + manufacturing documentation.
5. **Regulatory Support (Weeks 41-52)**: Prepare technical file, assist with clinical studies, respond to regulatory queries. Deliverable: Submission-ready documentation package.
## Troubleshooting
**Q: Antibody pair shows poor sensitivity?**
A: Screen additional antibody clones (minimum 10 capture × 10 detection combinations). Consider signal amplification (biotin-streptavidin, tyramide). Evaluate alternative labels (Eu³⁺, quantum dots, gold enhancement).
**Q: Matrix effects cause false positives?**
A: Add matrix blockers (casein, fish gelatin, proprietary polymers) to sample buffer. Optimize wash stringency. Include heterophilic antibody blockers for human samples.
**Q: Manufacturing scale-up fails?**
A: Document all critical process parameters during R&D. Implement statistical process control (SPC). Conduct design of experiments (DOE) to identify robust operating ranges.
## Conclusion & OEM/ODM Services
Successful custom assay development requires clear milestones, regular communication, and experienced partners. Due Bio has supported POCT manufacturers since 1987 with complete IVD Reagents OEM/ODM services from concept to commercialization.
For custom development projects, contact: **medtiger@foxmail.com**
Visit: www.duebio.com